Global Biospecimen Contract Research Services Market Size is valued at USD 5.0 Billion in 2024 and is predicted to reach USD 17.7 billion by the year 2034 at a 13.6% CAGR during the forecast period for 2025 to 2034.
Biospecimen Contract Research Services Market Size, Share & Trends Analysis Report By Biospecimen Type (Oncological Studies, Non-Oncological Studies), By Therapeutic Area, By Region, And By Segment Forecasts, 2025 to 2034
Increased investment in pharmaceutical R&D, an increase in the number of clinical trials, and the high cost of in-house drug development are driving growth in the Biospecimen Contract Research Services Market (encouraging pharma-biotech companies to outsource). Growth in the drugs and biologics market despite the COVID-19 pandemic, rising demand for specialized testing services among end-users, and the need for novel clinical trial designs for complex cell and gene therapies are all expected to provide a wide range of growth opportunities for market participants.
Most pharmaceutical, biopharmaceutical, and medical device companies continue to invest heavily in developing new drugs and devices. In the pharmaceutical industry, R&D is essential, and pharmaceutical firms invest in research and development to bring high-quality, innovative products to market. The increased investment in biologics and biosimilars by biopharmaceutical companies is attributed to an increase in the number of approved products globally. Biologics like proteins, peptides, and monoclonal antibodies currently account for more than half of all drug candidates in the discovery stage.
The Biospecimen Contract Research Services market is segmented into the biospecimen types and therapeutics areas. Based on the type of biospecimen types, the market is segmented into oncological and non-oncological studies. The oncological studies are further segmented into FFPE Tissue, Frozen Tissue, Plasma / Serum and Other Biospecimens. The non-oncological studies are further segmented into Blood Products, Human Tissue and Other Biospecimens. The therapeutics area segment includes Oncological Disorders, Neurological Disorders, Cardiovascular Disorders and Other Therapeutic Areas.
The oncological studies segment is accounted as a significant contributor in the Biospecimen Contract Research Services market. The demand for biospecimens in cancer research has increased, but there is little data on biospecimen usage trends. These data are required to forecast future demand. This was due to larger cohort sizes for both frozen and FFPE tissues. For decades, Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens have been a mainstay of research and therapeutic applications. FFPE is a type of biopsy specimen preservation and preparation that aids in the examination, experimental research, and diagnostic/drug development. To preserve the proteins and vital structures within the tissue, a tissue sample is first fixed in formaldehyde, also known as formalin. It is then embedded in a paraffin wax block, making it easier to cut slices of the required sizes for examination on a microscopic slide.
Oncology, or the study of cancer and tumours, has made significant advancements in the prevention, treatment, and prognosis of many childhood cancers. Despite this progress, cancer remains the leading cause of death in children. Childhood cancer differs from adult cancers in terms of development, treatment, response to therapy, therapy tolerance, and prognosis. In most cases, childhood cancer responds better to treatment, the child can tolerate more aggressive treatment, and the forecast is better.
North America dominated the global biospecimen contract research services market. North America's dominance in this market is primarily due to the market's rapid growth, pharmaceutical and biopharmaceutical companies' increased focus on outsourcing, and an increase in the number of clinical trial activities in the region. The rising popularity of precision/personalized medicine and genetic testing has been a major driving force in the region's market. Biobanks have long been essential in biomedical research. Over the last few decades, there have been several advancements in the platforms and tools used in genetic studies. This has resulted in increased clinical lab demand for biospecimens to develop assays for genetic testing in this region.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 5.0 billion |
| Revenue Forecast In 2034 | USD 17.7 billion |
| Growth Rate CAGR | CAGR of 13.6 % from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Biospecimen Type, By Therapeutic Area |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; India; Japan; Brazil; Mexico ; France; Italy; Spain; China; South Korea; South East Asia |
| Competitive Landscape | BioChain Institute, BioIVT, Boca Biolistics, Creative Bioarray, Cureline, Discovery Life Sciences, Infinity BiologiX, Precision for Medicine, Inc., PrecisionMed, Inc., Medicover, National BioService, ICON plc, The MT Group, Eolas Biosciences Co. Ltd, Indivumed GmbH, Ardent Clinical Research Services, Capital Biosciences, Inc., GR BioResearch, REPROCELL, Trans-Hit Bio (Azenta US, Inc.) and iSpecimen |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
By Service Type
By Specimen Type
By Therapeutic Area
By End-User
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.